You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

934 Results
Guidelines and Advice
Status: Current
Jun 2021
Document
Jun 2021
Document
Jun 2021
Guidelines and Advice
Status: Current
Version: 2
Dec 2024
Document
Jun 2021
Document
Jun 2021
Document
Jun 2021
Document
Jun 2021
Document
Jul 2021
Document
Jul 2021
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    selpercatinib - For the treatment of metastatic RET fusion-positive non-small cell lung cancer (NSCLC)
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
selpercatinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Apr 2025
Document
Jul 2021

Pages